Amir Weisberg – Chief Executive Officer

Mr. Weisberg has been leading PolyPid since 2010 and has 20 years of experience as an entrepreneur and CEO of start-up companies with two financial exits. Prior to PolyPid, Mr. Weisberg managed start-up companies in the Life Science sphere, from incubator stage to clinical trials, including leading the financing rounds for these companies.

Taunia Markvicka, PharmD, MBA - Chief Operating Officer

Taunia has over 25 years of pharmaceutical experience from regulatory/clinical to new product planning and commercialization. Taunia was previously Chief Commercial Officer (CCO) at Symbiomix Therapeutics, a venture funded company, sold to Lupin Pharmaceuticals. She was also CCO at Pacira Pharmaceuticals, taking the company public and successfully launching EXPAREL®. Prior to Pacira, Taunia held commercial leadership positions with Advantage Healthcare, The Medicines Company, and Allergan (formerly Watson). She started her career as a hospital pharmacist and joined the pharmaceutical industry following the completion of a post-doctorate fellowship with Novartis (former Sandoz Pharmaceuticals). Taunia has over 25 years of pharmaceutical experience from regulatory/clinical to new product planning and commercialization. Taunia earned her doctorate in pharmacy from the University of Nebraska Medical Center and post-doctoral fellowship with Rutgers University/Sandoz Pharmaceuticals, after completing her Bachelors, Pharmacy at Creighton and becoming a registered pharmacist. She went on to complete her master’s in business administration at St. Joseph’s University.